Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines
Radiotherapy and Oncology, ISSN: 0167-8140, Vol: 111, Issue: 3, Page: 468-474
2014
- 35Citations
- 192Usage
- 42Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations35
- Citation Indexes35
- 35
- CrossRef12
- Usage192
- Downloads184
- Abstract Views8
- Captures42
- Readers42
- 42
Article Description
Glioblastoma multiforme (GBM) represents the most common and deadly primary brain malignancy, particularly due to temozolomide (TMZ) and radiation (RT) resistance. To better understand resistance mechanisms, we examined global kinase activity (kinomic profiling) in both treatment sensitive and resistant human GBM patient-derived xenografts (PDX or “xenolines”).
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S016781401400173X; http://dx.doi.org/10.1016/j.radonc.2014.04.010; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84905225833&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/24813092; https://linkinghub.elsevier.com/retrieve/pii/S016781401400173X; https://scholarworks.wm.edu/rbc_facwork/12; https://scholarworks.wm.edu/cgi/viewcontent.cgi?article=1010&context=rbc_facwork; http://www.thegreenjournal.com/article/S0167-8140(14)00173-X/abstract; http://linkinghub.elsevier.com/retrieve/pii/S016781401400173X; https://secure.jbs.elsevierhealth.com/action/getSharedSiteSession?redirect=http%3A%2F%2Fwww.thegreenjournal.com%2Farticle%2FS0167-8140%2814%2900173-X%2Fabstract&rc=0&code=radion-site; http://acw.elsevier.com/SSOCore?return=https%3A%2F%2Fsecure.jbs.elsevierhealth.com%2Faction%2FconsumeSsoCookie%3FredirectUri%3Dhttp%253A%252F%252Fwww.thegreenjournal.com%252Faction%252FconsumeSharedSessionAction%253FJSESSIONID%253Daaa_7fsyCzQ04-ZPgjnxv%2526MAID%253DArEdGYcIXsdYInKv9%25252B9EHA%25253D%25253D%2526SERVER%253DWZ6myaEXBLF%25252FdY29RpN4fA%25253D%25253D%2526ORIGIN%253D16060517%2526RD%253DRD; http://acw.elsevier.com/SSOCore/?return=https%3A%2F%2Fsecure.jbs.elsevierhealth.com%2Faction%2FconsumeSsoCookie%3FredirectUri%3Dhttp%253A%252F%252Fwww.thegreenjournal.com%252Faction%252FconsumeSharedSessionAction%253FJSESSIONID%253Daaa_7fsyCzQ04-ZPgjnxv%2526MAID%253DArEdGYcIXsdYInKv9%25252B9EHA%25253D%25253D%2526SERVER%253DWZ6myaEXBLF%25252FdY29RpN4fA%25253D%25253D%2526ORIGIN%253D16060517%2526RD%253DRD; https://secure.jbs.elsevierhealth.com/action/consumeSsoCookie?redirectUri=http%3A%2F%2Fwww.thegreenjournal.com%2Faction%2FconsumeSharedSessionAction%3FJSESSIONID%3Daaa_7fsyCzQ04-ZPgjnxv%26MAID%3DArEdGYcIXsdYInKv9%252B9EHA%253D%253D%26SERVER%3DWZ6myaEXBLF%252FdY29RpN4fA%253D%253D%26ORIGIN%3D16060517%26RD%3DRD&acw=&utt=
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know